HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hoffer, P. B. Articles by Thakur, M. Search for Related Content PubMed Articles by Hoffer, P. B. Articles by Thakur, M.

Effect of Desferoxamine on Tissue and Tumor Retention of Gallium-67: Concise Communication

Yale University School of Medicine, New Haven, Connecticut

Correspondence: For reprints contact: Paul B. Hoffer, Sec. of Nuclear Medicine, Dept. of Diagnostic Radiology, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06510.

ABSTRACT

Desferoxamine (DEF) was administered intramuscularly (0.25 mg/g body weight) to mice harboring a Cloudman's melanoma S-91 3 hr before, simultaneously with, and 3 hr after i.v. injection of Ga-67 citrate (approximately I µCi/g body weight). Relative Ga-67 retention was compared with that in non-DEF controls at 24 hr. The chemical nature of Ga-67 excreted in urine following DEF was also studied in healthy mice. Desferoxamine administered 3 hr before Ga-67 had little effect on radiogallium localization; administration coincident with or 3 hr after radiogallium resulted in decreased retention at 24 hr. The effect was most profound when Ga-67 and DEF were administered simultaneously. In DEF-injected animals Ga-67 was excreted in the urine as a Ga-67-DEF complex. When DEF was administered 3 hr after Ga-67, there was a trend to greater tumor-to-blood activity ratios (.2 > p > .1).